Biolamina
Health
· Headquartered in Sweden 🇸🇪
Track Biolamina
— get Health deals in free daily digest
Overview
Biolamina, a Stockholm-based biotech company, has secured a €20 million financing commitment from the European Investment Bank (EIB) to enhance the development of cell therapies for chronic diseases. This venture debt will support the scaling of their laminin-based cell culture substrates, which facilitate reliable cell growth and differentiation. The funding aims to expand manufacturing capabilities and product offerings, addressing challenges in developing treatments for conditions like diabetes and cancer.
Products
Loading...
Synthesising company profile
Reading press coverage to extract founders, customers, traction signals and competitive positioning…
Recent Announcements
Biolamina, a Stockholm-based biotech company, has secured a €20 million financing commitment from the European Investment Bank (EIB) to enhance the development of cell therapies for chronic diseases. This venture debt will support the scaling of their laminin-based cell culture substrates, which facilitate reliable cell growth and differentiation. The funding aims to expand manufacturing capabilities and product offerings, addressing challenges in developing treatments for conditions like diabetes and cancer.
More Health Deals
Market Map
View thousands of companies by category in our market map:
